Results 101 to 110 of about 24,187 (251)

Tubulointerstitial nephritis and uveitis syndrome in children: What to keep an eye on

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose The purpose of this study was to determine the disease course in patients with tubulointerstitial nephritis and uveitis (TINU) syndrome, focusing on long‐term outcome and the incidence of complications such as chronic kidney disease (CKD).
Jytte Hendrikse   +4 more
wiley   +1 more source

Seronegative spondyloarthropathies : a review : part II: genetics and pathogenesis [PDF]

open access: yes, 1993
In none of the spondyloarthropathies is the pathogenesis well understood. Much of the investigation into the aetio-pathogenesis of these diseases has focused on the association with HLA-B27 and the known triggering potential of certain infectious agents.
Borg, Andrew A.   +2 more
core  

Accidental intralenticular dexamethasone intravitreal implant with the resolution of macular oedema in central retinal vein occlusion [PDF]

open access: yes, 2016
No abstract ...
Abdolrahimzadeh, Solmaz   +3 more
core   +1 more source

The Swedish National Pediatric Cataract Register (PECARE): Coexisting systemic disorders 2007–2023

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose To analyse the frequency and type of coexisting systemic disorders in children operated on for cataract in Sweden. Methods Data were retrieved from the Swedish National Pediatric Cataract Register (PECARE) for children operated between January 1, 2007, and December 31, 2023 (n = 975), including follow‐ups at age 1, 2, 5 and 10 ...
David Wackerberg   +9 more
wiley   +1 more source

Comprehensive Treatment of Noninfectious Uveitis Accompanied by Macular Edema with the Use of Autologous Platelet-Rich Plasma

open access: yesActa Biomedica Scientifica, 2019
Background. A common cause of visual impairment in patients with non-infectious uveitis is macular edema, developing in 38–84 % of cases. Plasma enriched with platelets is widely used in various branches of medicine, the effectiveness of its use in the ...
N. S. Arbenyeva   +4 more
doaj   +1 more source

Gender and uveitis in patients with multiple sclerosis. [PDF]

open access: yes, 2014
Multiple sclerosis (MS), a demyelinating disease of the central nervous system, is more commonly seen in women. It has been associated with both anterior and intermediate uveitis as well as retinal vasculitis.
Goldstein, Debra A, Gordon, Lynn K
core   +3 more sources

Infection control in the brain and the eye

open access: yesActa Ophthalmologica, EarlyView.
Abstract The Central Nervous System (CNS), comprising the brain and the eye, is considered to have a ‘privileged’ mechanism for dealing with immunological challenge (immune privilege, IP). CNS IP has been revealed through experiments using foreign protein antigens and cell and tissue alloantigens (grafts), but evidence for a role for IP in modulating ...
John V. Forrester   +2 more
wiley   +1 more source

Late observation of the neuroprotective effect of citicoline in uveitis: an impact on the ultrastructure of the choriocapillaris, retina and optic nerve in rabbits

open access: yesJournal of Ophthalmology
Purpose: To evaluate the ultrastructure of the choriocapillaris, retina and optic nerve (ON) in citicoline-treated versus non-treated rabbits at the late time point after inducing non-infectious anterior and intermediate uveitis.
V. Ulianov, I. Horianova, N. Molchaniuk
doaj   +1 more source

Hypothyroidism and non-infectious uveitis [PDF]

open access: yesEye, 2018
Shorya Vardhan, Azad   +3 more
openaire   +2 more sources

Twelve‐Month Real‐World Outcomes of Faricimab for Treatment‐Naive Neovascular AMD in Australia

open access: yesClinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background To provide insights into the effectiveness and safety of faricimab for treatment‐naïve eyes with neovascular age‐related macular degeneration (nAMD). Methods A retrospective cohort study using a prospectively‐designed registry. Treatment‐naïve eyes with nAMD in Australia starting treatment with faricimab between Jan 2023–Sep 2024 ...
Mark Gillies   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy